Shanghai Cell Therapy Group Co., a Chinese biotech company, has completed an RMB925 million (US$135.71 million) series C round of financing, led by China Pacific Insurance Company, Haier Capital and China Industrial Asset Management Limited, according to an announcement yesterday.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Read 2 Articles for Free with a Basic Account
Gain limited and restricted access to China Money Network.Register Basic Account
Subscribe for an annual subscription!
Enjoy comprehensive and exclusive data you can't find elsewhere!More Info
Already have an account or paid subscription?